Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Determinants of substrate specificity for factor XIII

J McDonagh1, H Fukue

  • 1Department of Pathology, Beth Israel Hospital, Boston, Massachusetts, USA.

Seminars in Thrombosis and Hemostasis
|January 1, 1996
PubMed
Summary

This study used a unique antibody to explore how factor XIIIa interacts with different substrates like fibrin, fibronectin, and alpha 2-plasmin inhibitor. The antibody specifically targets a 54-kDa region of factor XIIIa's active form and inhibits fibrin and fibronectin binding but not alpha 2-PI. The findings suggest that fibrin and fibronectin share a common exosite binding domain, while alpha 2-PI uses a different one. The antibody also reduced alpha-polymer formation, which is important for normal fibrinolysis. These insights help clarify how factor XIIIa contributes to clot stabilization and may inform future research on coagulation disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta interferon therapy for chronic hepatitis C in patients with haemophilia and other haemorrhagic disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Co-existence of juvenile-onset systemic lupus erythematosus and juvenile myasthenia gravis.

Lupus·2015
Same author

Child-murder narratives in George Eliot's Adam Bede: embedded histories and fictional representation.

Nineteenth-century literature·2010
Same author

A Case of Pachydermatocele.

Proceedings of the Royal Society of Medicine·2009
Same author

Learning empathy: medical school and the care of the dying patient.

Journal of palliative medicine·2005
Same author

Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention.

Neuromuscular disorders : NMD·2005

Area of Science:

  • Coagulation and fibrinolysis research in hematology
  • Enzymatic substrate specificity in molecular biology

Background:

Understanding how plasma factor XIIIa interacts with different substrates is essential for clarifying its role in coagulation and fibrinolysis. Prior research has shown that factor XIIIa catalyzes epsilon-(gamma-glutamyl)lysyl bonds, linking proteins like fibrin, fibronectin, and alpha 2-plasmin inhibitor. However, the specific mechanisms governing these interactions remain unclear. No prior work had resolved how distinct substrates bind to factor XIIIa with varying affinities. This gap motivated the development of a unique antibody to probe these interactions. The antibody's specificity for a 54-kDa region of A*2 offered a novel tool for investigation. Existing studies lacked detailed insights into how exosite binding contributes to substrate specificity. This paper's contribution lies in using this antibody to distinguish between binding domains for different substrates. The findings may help clarify how factor XIIIa regulates fibrinolytic processes.

Purpose Of The Study:

The aim of this study was to investigate the determinants of substrate specificity for factor XIIIa using a novel antibody. The specific problem addressed was the unclear mechanism by which factor XIIIa interacts with fibrin, fibronectin, and alpha 2-plasmin inhibitor. The motivation for this work stemmed from the need to better understand how these interactions influence coagulation and fibrinolysis. The antibody's unique specificity for the 54-kDa region of A*2 made it a suitable tool for this purpose. The study sought to determine whether exosite binding domains differ among substrates. The researchers proposed that fibronectin and fibrin share a similar binding mechanism, while alpha 2-PI uses a distinct one. This approach allowed for a detailed comparison of substrate interactions. The findings could provide insights into how factor XIIIa contributes to fibrin clot stabilization.

Keywords:
Factor XIIIa functionExosite binding mechanismsFibrin crosslinkingPlasmin inhibitor interactions

Frequently Asked Questions

The antibody inhibits exosite binding of fibrin and fibronectin but not alpha 2-PI.

The antibody specifically targets the 54-kDa region of factor XIIIa's active form.

This region is critical for exosite binding of fibrin and fibronectin.

The antibody reduces fibronectin crosslinking to fibrin clots.

Alpha-polymer formation is necessary for normal fibrinolysis rates.

Related Experiment Videos

Main Methods:

The study utilized a unique antibody specific to the middle 54-kDa region of factor XIIIa's active form (A*2). This antibody was tested for reactivity against zymogen (A2) and inactive intermediate (A'2) forms. The antibody's effect on A*2-fibrin complex formation was assessed using functional assays. The same antibody was used to study interactions with fibronectin and alpha 2-plasmin inhibitor. The researchers measured the extent of fibronectin crosslinking to fibrin clots. They also evaluated the amount of alpha 2-PI crosslinked to fibrin clots. The antibody's impact on alpha-polymer formation was analyzed. These methods allowed the team to distinguish between binding domains for different substrates.

Main Results:

The antibody inhibited the formation of A*2-fibrin complexes, indicating its effect on exosite binding. It similarly blocked fibronectin-factor XIIIa interactions, reducing fibronectin crosslinking to fibrin clots. However, alpha 2-PI crosslinking to fibrin clots remained unaffected. These results suggest that fibronectin and fibrin share a common exosite binding domain. In contrast, alpha 2-PI likely binds through a different region. The antibody also reduced alpha-polymer formation, a key step in fibrin stabilization. This finding implies that both alpha 2-PI-alpha chain crosslinking and alpha-polymer formation are necessary for normal fibrinolysis. The antibody's specificity for the 54-kDa region of A*2 enabled these insights.

Conclusions:

The authors concluded that the antibody inhibits exosite binding of fibrin and fibronectin in a similar manner. However, alpha 2-PI binding involves a distinct exosite domain. This finding supports the idea that different substrates interact with factor XIIIa through distinct mechanisms. The antibody's specificity allowed for a clear distinction between these interactions. The study showed that both alpha 2-PI-alpha chain crosslinking and alpha-polymer formation are necessary for normal fibrinolysis. These results suggest that exosite binding is a critical determinant of substrate specificity. The findings may help clarify how factor XIIIa contributes to clot stability. The antibody proved to be a valuable tool for studying these interactions.

Failed At:

2026-07-10T15:00:50.694182+00:00

Alpha 2-PI uses a distinct exosite binding domain compared to other substrates.